Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2018-03-06 Earnings Release
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 6, 2018, reporting the results of operations and financial condition for the quarter and fiscal year ended December 31, 2017. It includes a press release as an exhibit. The text explicitly states that the information is a press release announcing financial results, not the full earnings report itself. The document length is 3388 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. The document is not a full Annual Report (10-K) or Interim Report (IR), but rather an initial announcement of quarterly/fiscal year financial results. Therefore, the appropriate classification is Earnings Release (ER).
2018-03-06 English
SC 13G/A
Major Shareholding Notification
2018-02-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a short filing (3026 characters) reporting an event related to a press release about an FDA decision on a drug application. It references the press release as an exhibit and does not contain detailed financial statements or comprehensive analysis. The document is primarily an announcement of an event rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-02-20 English
SC 13G/A
Major Shareholding Notification
2018-02-14 English
SCHEDULE 13G
Major Shareholding Notification
2018-02-14 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-02-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.